Entertainment news and discussion on TalkFuse.
Science Corporation raises $400 million at a $3.5 billion valuation
Science Corporation, a medical technology startup founded by former Neuralink president Max Hodak, has raised $400 million in a funding round that values it at $3.5 billion. The money will support efforts to bring its vision-restoring device to the US and advance its broader aim of developing technology that connects directly with the brain.
Its first product, PRIMA, combines an implantable chip and wearable equipment to help some people with age-related macular degeneration recover vision. It is approved and available in Germany, and is being trialled for Stargardt disease; the company plans to seek US access through the FDA’s Humanitarian Device Exemption. Science is also designing initial human trials of a bio-hybrid sensor made from cultured neurons and silicon, which it says could eventually help treat Parkinson’s disease and other conditions.
In short
- Science Corporation raised $400 million at a $3.5 billion valuation.
- Its PRIMA device helps some people with macular degeneration recover vision.
- The company is planning early human trials of a neuron-silicon brain sensor.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The funding could accelerate access to a device that may restore some vision for people with serious retinal disease, while supporting research into treatments for other conditions. Backers may see substantial private investment as a way to move promising technology through trials and towards patients, provided it is assessed carefully for safety and effectiveness.
The case against
A high valuation and large funding round may encourage rapid development and ambitious claims before the technology’s benefits and risks are well established. Because the work involves brain interfaces and cultured neurons, cautious observers may favour rigorous independent evidence, regulatory scrutiny and clear limits on claims about future treatments before broader adoption.
Explained simply
Science Corporation is a medical technology company founded by Max Hodak, who previously led Neuralink. It develops devices that interact directly with the brain and nervous system, an area of research sometimes called neurotechnology.
Its first product, PRIMA, pairs a small implant with wearable equipment to help some people with age-related macular degeneration, a condition that damages central vision. The device is available in Germany, while US access would require review by the Food and Drug Administration; the company is also studying it for Stargardt disease, a separate inherited eye condition. More broadly, the company is exploring sensors that combine living nerve cells with silicon, with possible applications in neurological conditions.
Read the full article at the source →
Originally published by TechCrunch as “Science Corporation’s brain tech is worth $3.5 billion after new funding”.